Safety and Efficacy of an Oxytocin Gel and an Equivalent Gel but Without Hormonal Ingredients (Vagivital® Gel) in Postmenopausal Women with Symptoms of Vulvovaginal Atrophy: A Randomized, Double-Blind Controlled Study
Aino Fianu Jonasson,1 Marie Bixo,2 Inger Sundström Poromaa,3 Mikael Åstrom4 1Department of Clinical Sciences, Intervention and Technology, Division of Obstetrics and Gynecology, Karolinska Institute, Stockholm, Sweden; 2Department of Clinical Sciences, Obstetrics and Gynecology, U...
Guardado en:
Autores principales: | Fianu Jonasson A, Bixo M, Sundström Poromaa I, Åstrom M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f18411d8cec34f15968ada88e01f7d9d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
An Open, Uncontrolled Pilot Study on 12-Week Use of VagiVital for Treatment of Vulvovaginal Atrophy in Breast Cancer Patients Undergoing Adjuvant Aromatase-Inhibitor Therapy
por: Jonasson AF, et al.
Publicado: (2021) -
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
por: Wurz GT, et al.
Publicado: (2014) -
Hormonal Approach for Postmenopausal Vulvovaginal Atrophy
por: Ana Paula Ferreira Costa, et al.
Publicado: (2021) -
Ionically cross-linked hyaluronic acid: wetting, lubrication, and viscoelasticity of a modified adhesion barrier gel
por: Katherine Vorvolakos, et al.
Publicado: (2010) -
First Use of Thermal Stabilized Hyaluronic Acid Injection in One-Year Follow-Up Patients with Genitourinary Syndrome
por: Garavaglia E, et al.
Publicado: (2020)